Cardlytics, Inc. (NASDAQ:CDLX) Director Scott D. Grimes sold 3,000 shares of the business’s stock in a transaction dated Monday, July 19th. The stock was sold at an average price of $117.48, for a total transaction of $352,440.00. Following the sale, the director now owns 239,674 shares in the company, valued at $28,156,901.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Scott D. Grimes also recently made the following trade(s):
- On Monday, May 17th, Scott D. Grimes sold 2,000 shares of Cardlytics stock. The stock was sold at an average price of $89.66, for a total transaction of $179,320.00.
- On Monday, May 3rd, Scott D. Grimes sold 2,000 shares of Cardlytics stock. The stock was sold at an average price of $134.39, for a total transaction of $268,780.00.
Shares of CDLX opened at $128.69 on Thursday. The company has a 50 day simple moving average of $112.87. The company has a debt-to-equity ratio of 0.24, a current ratio of 7.63 and a quick ratio of 7.63. The firm has a market capitalization of $4.23 billion, a P/E ratio of -54.07 and a beta of 2.61. Cardlytics, Inc. has a 52-week low of $55.89 and a 52-week high of $161.47.
A number of analysts have issued reports on CDLX shares. TheStreet upgraded shares of Cardlytics from a “d” rating to a “c-” rating in a research note on Monday, July 12th. Wells Fargo & Company raised Cardlytics from an “equal weight” rating to an “overweight” rating and set a $150.00 price objective for the company in a research report on Thursday, April 15th. Needham & Company LLC assumed coverage on Cardlytics in a research report on Friday, June 18th. They set a “buy” rating and a $135.00 price objective for the company. Craig Hallum boosted their price objective on Cardlytics from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, May 5th. Finally, Zacks Investment Research raised Cardlytics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 7th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $142.17.
A number of institutional investors and hedge funds have recently made changes to their positions in CDLX. JPMorgan Chase & Co. boosted its holdings in Cardlytics by 105.7% in the fourth quarter. JPMorgan Chase & Co. now owns 1,451,294 shares of the company’s stock valued at $207,202,000 after purchasing an additional 745,762 shares in the last quarter. Baillie Gifford & Co. acquired a new stake in shares of Cardlytics in the first quarter valued at approximately $48,890,000. BlackRock Inc. boosted its holdings in shares of Cardlytics by 17.1% in the first quarter. BlackRock Inc. now owns 2,399,457 shares of the company’s stock valued at $263,221,000 after acquiring an additional 350,590 shares during the period. Morgan Stanley boosted its holdings in shares of Cardlytics by 25.7% in the first quarter. Morgan Stanley now owns 1,034,055 shares of the company’s stock valued at $113,436,000 after acquiring an additional 211,201 shares during the period. Finally, Principal Financial Group Inc. acquired a new stake in shares of Cardlytics in the first quarter valued at approximately $10,360,000. 92.20% of the stock is owned by hedge funds and other institutional investors.
Cardlytics Company Profile
Cardlytics, Inc operates an advertising platform within financial institutions digital channels that include online, mobile, email, and various real-time notifications in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Featured Story: What is the formula for the cash asset ratio?
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.